Current Opportunities

Eidolon Therapeutics is an early-stage biotech venture engineering microbial proteins to address one of oncology's most persistent problems: immunotherapy resistance. Founded by scientists from the Institute of Cancer Research and Imperial College London, the company is developing its lead candidate — a combination therapy targeting pancreatic cancer — with promising preclinical results and a clear path toward clinical validation.

The team is small, scientific, and operating at the frontier of what is known. The work is consequential

MediSieve uses nanoengineered magnetic particles to filter harmful cells, pathogens, and inflammatory cytokines directly from a patient's bloodstream. The technology is platform in nature — with a growing pipeline of applications in conditions where existing treatments fall short. Based in White City, London, the company has raised $10M to date and operates an established partnership model with large industry players.

Go Assistive Technology is an early-stage medtech venture building practical prosthetic solutions for markets where affordability and access are structural barriers, not edge cases. The company was founded within the entrepreneurial ecosystem of Imperial College London and is now moving from product development into commercial structure.

We are a small team operating with a clear mission and real constraints. The work here is direct, honest, and consequential.